Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
1.135
+0.015 (1.34%)
At close: Nov 20, 2026, 4:00 PM EST
1.102
-0.033 (-2.87%)
After-hours: Nov 20, 2026, 7:37 PM EST
Nkarta Employees
Nkarta had 103 employees as of September 30, 2026. The number of employees decreased by 2 or 1.90% compared to the same quarter last year. That makes Nkarta the 31,262nd largest employer in the world and 3,979th in the United States.
Employees
103
Change (1Y)
-2
Growth (1Y)
-1.90%
Revenue / Employee
n/a
Profits / Employee
-$1,251,796
Market Cap
81.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 103 | -2 | -1.90% |
| Jun 30, 2026 | 106 | -4 | -3.64% |
| Mar 31, 2026 | 108 | -1 | -0.92% |
| Dec 31, 2025 | 108 | -49 | -31.21% |
| Sep 30, 2025 | 105 | -54 | -33.96% |
| Jun 30, 2025 | 110 | -40 | -26.67% |
| Mar 31, 2025 | 109 | -41 | -27.33% |
| Dec 31, 2024 | 157 | 7 | 4.67% |
| Sep 30, 2024 | 159 | -8 | -4.79% |
| Jun 30, 2024 | 150 | -19 | -11.24% |
| Mar 31, 2024 | 150 | -15 | -9.09% |
| Dec 31, 2023 | 150 | -13 | -7.98% |
| Sep 30, 2023 | 167 | 21 | 14.38% |
| Jun 30, 2023 | 169 | 42 | 33.07% |
| Mar 31, 2023 | 165 | 30 | 22.22% |
| Dec 31, 2022 | 163 | 27 | 19.85% |
| Sep 30, 2022 | 146 | 13 | 9.77% |
| Jun 30, 2022 | 127 | 11 | 9.48% |
| Mar 31, 2022 | 135 | 28 | 26.17% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Seer, Inc. | 124 |
| Rani Therapeutics Holdings | 71 |
| TuHURA Biosciences | 22 |
| Black Diamond Therapeutics | 21 |
| Tenax Therapeutics | 16 |
| Cingulate | 14 |
| Tiziana Life Sciences | 10 |
NKTX News
- 11 days ago - Nkarta announces integrated safety results from 40 patients treated with NKX019 - TheFly
- 11 days ago - Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026 - GlobeNewsWire
- 13 days ago - Nkarta Transcript: Study update - Transcripts
- 13 days ago - Nkarta Press release: Study update - Filings
- 13 days ago - Nkarta Slides: Study update - Filings
- 13 days ago - Nkarta announces initial clinical data from Ntrust clinical trial program - TheFly
- 13 days ago - Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence - GlobeNewsWire
- 15 days ago - Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 - GlobeNewsWire